Somatic Symptom and Related Disorders

• Hypervigilance to bodily sensations with amplified interoceptive processing: Individuals with SSRDs demonstrate heightened attention to internal bodily signals due to dysfunction in anterior insula and anterior cingulate cortex regions responsible for interoceptive awareness. Neuroimaging studies show increased activation in these regions during experimental pain stimuli. This hypervigilance creates a vicious cycle: minor physiological variations (normal gastric motility, transient muscle tension, innocuous heart rate fluctuations) are detected and interpreted as indicators of serious disease. The reticular activating system, responsible for filtering irrelevant stimuli, fails to habituate to benign bodily signals, resulting in sustained attention to symptoms. This mechanism explains why reassurance and negative test results fail to reassure patients—their brains continue to amplify normal bodily noise into perceived pathology.

• Maladaptive illness beliefs and catastrophic misinterpretation: The medial prefrontal cortex and amygdala show hyperactivity in SSRDs when patients process symptom-related information, reflecting exaggerated threat assessment. Faulty attributional biases cause patients to misinterpret normal bodily sensations as evidence of serious disease (e.g., interpreting palpitations as cardiac disease, abdominal bloating as cancer). These illness beliefs become self-reinforcing through cognitive biases including confirmation bias (selectively attending to information confirming disease presence), selective negative attention (ignoring contradictory evidence), and overestimation of probability and severity of harm. The dorsal anterior cingulate cortex dysfunction impairs error monitoring and emotional regulation, preventing patients from correcting these misinterpretations. This neurobiological framework explains why SSRDs persist despite normal diagnostic testing—the disorder lies in cognitive interpretation, not organic pathology.

• Altered pain modulation and central sensitization: Dysfunction in descending inhibitory pain pathways (mediated by serotonin and norepinephrine from the brainstem) and elevated levels of substance P in cerebrospinal fluid create a state of central sensitization. The anterior insula shows reduced gray matter volume, correlating with symptom severity, and demonstrates abnormal connectivity with the prefrontal cortex regions responsible for pain suppression. Low serotonin and norepinephrine availability reduces top-down inhibition of nociceptive signals at the spinal cord and brainstem levels, allowing normal sensory input to be processed as painful. Additionally, microglial activation in the central nervous system may amplify pain signaling through pro-inflammatory cytokine production (IL-6, TNF-α, IL-1β). This explains why SSRDs frequently co-occur with chronic pain conditions and why pain amplification disproportionate to objective findings characterizes the presentation.

• Dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis and chronic stress response: Childhood adversity, trauma, and ongoing psychological stress lead to both hyperactivation and dysregulation of the HPA axis, resulting in altered cortisol dynamics (flattened diurnal curve, elevated morning cortisol). Elevated glucocorticoid levels chronically upregulate inflammatory response genes and impair immune regulation, creating a pro-inflammatory state with elevated CRP, IL-6, and TNF-α. This systemic inflammation contributes to genuine somatic symptoms including fatigue, myalgia, and cognitive dysfunction. Additionally, chronic HPA activation increases autonomic nervous system reactivity, heightening sympathetic tone and parasympathetic dysregulation, resulting in palpitations, dyspnea, and gastrointestinal symptoms. These neurobiological changes explain why SSRDs have measurable physiological correlates beyond psychological dysfunction alone.

• Negative reinforcement through avoidance and healthcare behaviors: Behavioral conditioning mechanisms perpetuate SSRDs through negative reinforcement, wherein avoidance of perceived triggers (activities, foods, situations) temporarily reduces anxiety but prevents habituation and extinction learning. Similarly, symptom-focused medical visits, investigations, and specialist referrals paradoxically reinforce illness identity and catastrophic illness beliefs rather than providing reassurance. Operant conditioning principles demonstrate that symptom display receives reinforcement through increased attention, healthcare access, and role identity as "sick patient." The limbic system's reward circuitry becomes sensitized to sickness behavior, creating powerful motivational drives toward health-seeking behavior that further cements the disorder's trajectory.

• Childhood adversity and early-life trauma: Adverse childhood experiences (ACE score ≥4), including physical/emotional/sexual abuse, neglect, parental separation, and household dysfunction, represent the most robust risk factor for SSRD development. These experiences lead to developmental disruption of interoceptive awareness, stress response regulation, and attachment patterns. Neurobiologically, early trauma causes permanent alterations in amygdala reactivity, hippocampal volume reduction, and prefrontal cortex dysfunction that persist into adulthood. The chronic activation of stress response systems during vulnerable developmental periods "programs" the nervous system toward heightened threat detection and reduced stress resilience. Approximately 50-60% of patients with SSRDs report significant early trauma histories.

• Genetic predisposition and familial aggregation: Twin and family studies demonstrate approximately 50% heritability for somatic symptom disorder and high rates of comorbid anxiety, depression, and personality disorders in first-degree relatives. Polymorphisms in genes regulating serotonin (5-HTTLPR), catecholamine, and dopamine systems influence individual vulnerability to developing SSRDs. The serotonin transporter gene short allele (S allele) is overrepresented in individuals with SSRDs, particularly when combined with environmental stressors. This gene-environment interaction explains why some individuals exposed to adversity develop SSRDs while others remain resilient—genetic variation in stress-response neurotransmitter systems modulates risk expression.

• Comorbid psychiatric disorders: Anxiety disorders (generalized anxiety disorder, panic disorder, social anxiety disorder) and major depressive disorder are present in 60-90% of SSRD cases, with panic disorder showing particularly strong association. These comorbidities share common neurotransmitter dysregulation (serotonin, GABA deficiency) and reinforce symptom amplification mechanisms. Patients with comorbid anxiety display heightened autonomic reactivity that generates genuine physical symptoms (chest pain from panic attacks, tremor from anxiety hyperarousal), which are then misinterpreted catastrophically, creating a recursive cycle. Personality disorders, particularly cluster B traits (histrionic, borderline) and avoidant patterns, are also frequently comorbid and complicate treatment.

• Medical illness and iatrogenic factors: Previous serious or chronic medical conditions (myocardial infarction, cancer, chronic pain syndromes, irritable bowel syndrome, fibromyalgia) significantly increase SSRD risk. Additionally, inadvertent iatrogenic perpetuation occurs when healthcare providers validate illness beliefs through excessive investigations, specialist referrals without clear clinical indication, and treatments of questionable necessity. Patients undergo medically unnecessary procedures, develop procedure-related complications, and accumulate diagnostic labels that reinforce illness identity. The "medical surveillance" itself becomes a risk factor—repeated imaging in asymptomatic or minimally symptomatic patients fuels health anxiety.

• Psychosocial stressors and life events: Acute or chronic psychosocial stressors (relationship conflict, occupational stress, financial instability, social isolation, loss and grief) precipitate or exacerbate SSRDs. These stressors generate negative emotional states that, in predisposed individuals, become somatized through heightened body scanning and symptom focus. Secondary gain factors, including disability benefits, healthcare attention, role identity, and escape from responsibilities, may maintain symptoms once established, though it should be emphasized that secondary gain is typically unconscious and SSRDs are not intentional or factitious in nature.

• Excessive somatic symptoms with disproportionate distress and functional impairment: Patients present with multiple symptoms spanning different organ systems (polysymptomatic presentations in >90% of cases), often including pain (musculoskeletal, headache, abdominal, pelvic), gastrointestinal complaints (nausea, bloating, diarrhea, constipation), and autonomic symptoms (palpitations, dyspnea, dizziness). The cardinal feature is disproportionate psychological response and cognitive preoccupation: symptoms cause anxiety far exceeding their objective severity, with patients ruminating extensively about disease meaning and catastrophizing about health consequences. Many patients describe a "body scan" behavior, constantly monitoring for new or changing symptoms. Functional impairment is typically substantial—patients report difficulty with work (absenteeism, reduced productivity), social activities, and self-care. The symptom intensity and distress often appear incongruent with clinical findings or investigation results, which can mislead clinicians into labeling patients as "difficult" or "attention-seeking."

• Excessive health-related anxiety and illness preoccupation: Patients demonstrate persistent, often overwhelming anxiety about having serious disease despite medical reassurance and negative test results. This anxiety is qualitatively different from simple health concern—it dominates cognitive processing throughout the day, causing significant distress. Patients engage in excessive health-related information seeking (internet research, medical websites, symptom databases), which paradoxically amplifies anxiety through exposure to rare disease descriptions matching their symptoms. They frequently report sleep disruption due to symptom focus and nighttime symptom monitoring. Many exhibit health anxiety that meets criteria for illness anxiety disorder (formerly hypochondriasis), the main distinction being that SSD patients experience multiple prominent somatic symptoms while illness anxiety disorder is characterized by high health anxiety with minimal or no somatic symptoms.

• Excessive health-related behaviors and medical consultation patterns: Patients exhibit maladaptive behaviors perpetuating the disorder, including frequent medical visits (sometimes multiple per month with different providers or specialists), unnecessary medication trials, avoidance of activities feared to exacerbate symptoms, and repeated reassurance-seeking from healthcare providers. Some patients develop extensive medication lists from accumulation of treatments trialed by different specialists. They may seek specialist evaluation (cardiology, gastroenterology, neurology) repeatedly despite normal workup, hoping that more intensive investigation will reveal the "true cause." Some patients become frustrated with medical practitioners, develop adversarial relationships with providers, and jump between practitioners seeking validation of disease beliefs. This pattern creates a frustrating dynamic wherein healthcare involvement becomes part of the pathology rather than the solution.

• Fatigue, sleep disturbance, and cognitive symptoms: Beyond primary somatic complaints, patients frequently report persistent fatigue despite adequate sleep, non-restorative sleep with frequent nighttime awakenings, and cognitive difficulties including concentration problems, memory complaints, and "brain fog." These symptoms may reflect genuine HPA axis dysregulation, chronic inflammation, and sleep architecture abnormalities documented on polysomnography. Patients often attribute fatigue to underlying serious disease, perpetuating illness beliefs, though fatigue frequently improves with treatment of the SSRD itself rather than interventions targeting putative physical causes.

• Physical examination findings: The physical examination is typically unremarkable relative to symptom severity. Notably, objective neurological findings are absent despite neurological symptom complaints. Vital signs are normal during symptomatic periods when anxiety would predict tachycardia or hypertension. Palpation often reveals normal examination findings, though some patients display high pain responses to light palpation suggestive of central sensitization or psychological amplification. Point tenderness may be widespread rather than anatomically consistent with recognized pathology. Some patients demonstrate positive findings on non-anatomical testing (e.g., homoeopathic signs, non-anatomical sensory loss) suggesting functional or psychological contributions. The examination should assess for features of anxiety (tremor, diaphoresis, hyperventilation) and identify any undiagnosed comorbid conditions requiring specific treatment.

• Important clinical variants—Illness anxiety disorder: Patients with illness anxiety disorder (estimated 1% population prevalence) are preoccupied with having or acquiring serious illness but experience minimal somatic symptoms. They focus intensely on bodily functions, interpret normal sensations as abnormal, and seek excessive medical care or conversely practice extreme avoidance of healthcare. Whereas SSD emphasizes somatic symptoms, illness anxiety disorder emphasizes health anxiety with few physical complaints. Both share the core mechanism of excessive illness beliefs but manifest with different symptom prominence.

• Important clinical variant—Conversion disorder (functional neurological symptom disorder): Patients present with neurological symptoms (weakness, paralysis, sensory loss, seizures, movement disorders, visual loss) without neurological pathology. Symptoms are inconsistent with recognized neurological disease, though they cause genuine distress and functional impairment. The hallmark is positive neurological signs (e.g., non-anatomical sensory loss, inconsistent strength testing) rather than negative findings alone. Functional magnetic resonance imaging demonstrates abnormal neural processing during symptom provocation. Importantly, patients are not consciously fabricating symptoms—the symptoms reflect an unconscious process converting psychological distress into neurological manifestations. This disorder often follows psychological stressors, trauma, or medical events.

• Clinical presentation in specific populations: Pediatric presentations often involve school refusal, activity avoidance, and parent-mediated checking behaviors. Older adults may present with multiple medically complex symptoms attributed to SSRD only after thorough medical evaluation excludes organic pathology; distinguishing age-related changes from pathological symptoms is clinically challenging. Male patients with SSRDs often present with pain-predominant presentations rather than the "medically unexplained" symptom emphasis, potentially leading to underdiagnosis.

• DSM-5 diagnostic criteria for Somatic Symptom Disorder: The diagnosis requires: (1) One or more somatic symptoms that are distressing or result in disruption of daily life; (2) Excessive thoughts, feelings, or behaviors related to the somatic symptoms, manifested by at least one of the following: disproportionate and persistent thoughts about seriousness of symptoms, persistently high anxiety about health or symptoms, excessive time and energy devoted to health concerns; (3) Duration of at least 6 months (symptoms need not be continuous throughout the 6-month period); (4) Not better explained by another medical or psychiatric disorder. The diagnosis does not require that symptoms be "medically unexplained"—patients may have genuine medical conditions, but the excessive health preoccupation and behavioral responses constitute the psychiatric diagnosis. Severity is specified: mild (1-2 criteria from group 2), moderate (2 or more criteria from group 2 with persistent symptoms), or severe (persistent symptoms lasting >2 years). This is a paradigm shift from DSM-IV, which emphasized medically unexplained symptoms; DSM-5 recognizes that SSRDs frequently coexist with medical conditions.

• Diagnostic criteria for Illness Anxiety Disorder: Requires preoccupation with having or acquiring serious illness despite minimal somatic symptoms, high anxiety about health, excessive health-related behaviors (checking, reassurance-seeking) or maladaptive avoidance behaviors, and duration ≥6 months. The key distinction from SSD is minimal somatic symptom burden; these patients worry about disease more than they experience symptoms. This diagnosis prevents misdiagnosis of health anxiety as generalized anxiety disorder and ensures appropriate targeted treatment.

• Diagnostic criteria for Conversion Disorder (Functional Neurological Symptom Disorder): Requires one or more symptoms of altered voluntary motor or sensory function, clinical or laboratory evidence of incompatibility between symptom and recognized neurological condition, symptom not better explained by medical/psychiatric disorder, and clinically significant distress or functional impairment. The symptom must show positive neurological signs—findings inconsistent with anatomical neurological pathways—rather than only negative findings. Examples include give-way weakness (strength suddenly collapses then recovers), homoeopathic sensory loss (abrupt boundary at midline), or non-anatomical distribution. Diagnostic certainty increases when positive signs are present; absence of signs does not exclude diagnosis but requires stronger evidence of functional mechanism.

• Clinical history pearls improving diagnostic accuracy: Detailed history should assess onset relationship to psychological stressors, medical events, or interpersonal conflict; presence of secondary gain factors; previous medical workups and results; medication trials and responses; family history of SSRDs, anxiety, depression, or medical illness; childhood adversity and trauma exposure; and current psychosocial stressors. A symptom timeline helps identify patterns—do symptoms cluster around stressful events? Do they resolve with stress reduction? Do they follow medical appointments or investigation results? A detailed medication history including over-the-counter supplements is essential, as many substances can generate somatic symptoms. Patients should be asked directly about health anxiety, catastrophic thoughts about symptoms, symptom checking behaviors, and functional impairment to assess for excessive health-related cognitions and behaviors. Time spent in medical visits should be quantified—more than

Immediate priorities

• Rule out and re-check for organic disease proportionate to red flags: SSD does not protect against medical illness, and treatment begins with a defensible baseline workup. New objective findings (fever, weight loss, focal deficits, abnormal labs) warrant targeted evaluation, not reflexive re-attribution to the psychiatric diagnosis.
• Screen for comorbid depression and suicidality: per APA practice principles, active suicidal ideation takes precedence over all somatic management.

First-line management (care-structure interventions)

• Single coordinating clinician with regularly scheduled, brief, time-contingent visits: appointments are booked at fixed intervals rather than triggered by new symptoms, which removes the negative-reinforcement loop described above. This is the highest-yield intervention and the usual "best next step" on exams.
• Legitimize symptoms, shift the goal from cure to function: acknowledge that symptoms are real and distressing, avoid saying "the tests are normal, so nothing is wrong," and set functional targets (work, exercise, sleep).
• Limit diagnostic testing and specialist referrals to objective indications: repeated normal testing reinforces illness identity and generates iatrogenic risk.
• Cognitive behavioral therapy: the psychotherapy with the strongest evidence base for SSD and illness anxiety disorder; targets catastrophic misinterpretation, body-checking, and reassurance-seeking. Mindfulness-based and acceptance/commitment approaches are reasonable alternatives.

Pharmacotherapy (adjunctive, second-line)

• SSRIs (e.g., fluoxetine, sertraline): first-choice drug class, particularly with comorbid depression or anxiety, which are present in most patients.
• SNRIs (e.g., duloxetine) or low-dose TCAs (e.g., amitriptyline): preferred when pain predominates, restoring descending serotonergic–noradrenergic inhibition.

Disorder-specific

• Functional neurological symptom disorder: clear, affirmative delivery of the diagnosis using the positive signs demonstrated at the bedside, then physiotherapy-led motor retraining; CBT is the best-supported treatment for functional (psychogenic non-epileptic) seizures.
• Factitious disorder: no drug therapy; avoid aggressive confrontation, protect the patient from further self-harm, and manage comorbid personality pathology. Factitious disorder imposed on another is child abuse and mandates a report to child protective services.

Avoid

• Opioids and benzodiazepines: no benefit, high dependence risk.
• Elective invasive procedures without objective indication.
• Repeated bare reassurance: transiently anxiolytic, long-term symptom-reinforcing.

Iatrogenic complications (the most important category)

• Procedural and surgical harm: repeated laparoscopy, endoscopy, or exploratory surgery for unexplained pain leads to adhesions, bowel injury, and anesthetic complications. Signalled by an operative history disproportionate to documented pathology.
• Cumulative radiation and contrast exposure: serial CT imaging carries malignancy risk; contrast-associated acute kidney injury presents as a creatinine rise after imaging.
• Opioid dependence and overdose — emergency: escalating doses for pain that has no nociceptive generator; miosis, somnolence, and respiratory depression signal overdose. Benzodiazepine co-prescription compounds risk.
• Polypharmacy from sequential specialist trials: drug–drug interactions, anticholinergic burden, QT prolongation. TCAs are lethal in overdose (wide QRS, arrhythmia, seizures) — relevant given high comorbid depression.
• Serotonin syndrome: with SSRI/SNRI plus tramadol or triptans; clonus, hyperreflexia, hyperthermia, agitation — emergency.

Complications of the disorder itself

• Missed organic disease from diagnostic anchoring — emergency: once labeled, new pathology is under-investigated. The signal is a change in symptom character, objective findings, or abnormal laboratory data.
• Major depression and suicide — emergency: chronic pain, disability, and adversarial care relationships drive suicidal ideation; always ask directly.
• Disability, unemployment, and social isolation: avoidance behavior prevents extinction learning and entrenches the sick role.
• Deconditioning and immobility complications in functional neurological disorder: prolonged functional paralysis causes contractures, disuse atrophy, pressure injury, and venous thromboembolism. Functional seizures mistaken for status epilepticus can lead to unnecessary intubation and ICU admission — a preventable iatrogenic emergency.

• Sepsis and abscess from self-injected material: polymicrobial or enteric organisms in an otherwise unexplained bacteremia.
• Surreptitious insulin use: hypoglycemia with high insulin and low C-peptide; sulfonylurea ingestion gives high insulin with high C-peptide plus a positive drug screen.
• Self-phlebotomy or anticoagulant ingestion: unexplained iron-deficiency anemia or coagulopathy correcting off the ward.
• Factitious disorder imposed on another: recurrent illness in a child that resolves during caregiver separation — reportable child abuse.

• DSM-5-TR shifted the emphasis from "medically unexplained" to excessive cognition and behavior: a patient with real coronary disease can still have somatic symptom disorder if the preoccupation is disproportionate. Duration is ≥6 months. This is the single most tested conceptual change.
• Distinguish the four look-alikes by symptom burden and intent: SSD = many distressing symptoms with disproportionate worry; illness anxiety disorder = intense fear of disease with minimal symptoms; factitious disorder = intentional falsification for the sick role with no external incentive; malingering = intentional falsification for an external incentive (money, drugs, avoiding jail/duty) and is not a psychiatric diagnosis.
• The single best next step in a stem describing frequent visits and normal workups: schedule regular, brief, time-contingent visits with one primary clinician — not more imaging, not another specialist, not a benzodiazepine.
• Conversion disorder is diagnosed by positive signs, not by exclusion: Hoover sign (hip extension weakness that normalizes with contralateral hip flexion), give-way weakness, non-anatomic sensory loss splitting exactly at the midline. La belle indifférence is a classic buzzword but is neither sensitive nor specific — a common distractor.
• First-line treatment is CBT; SSRIs/SNRIs are adjunctive and most useful for comorbid depression or anxiety, with SNRIs or low-dose TCAs favored when pain predominates.
• Never confront a factitious-disorder patient aggressively, and never simply discharge them: the tested answer is non-punitive confrontation with psychiatric involvement. Factitious disorder imposed on another obligates a report to child protective services — this is the association examiners test most.
• Exogenous insulin gives high insulin with low C-peptide; sulfonylurea gives high insulin, high C-peptide, and a positive sulfonylurea screen. This lab pair is the classic factitious hypoglycemia vignette.
• Do not tell the patient the symptoms are imaginary: symptoms are genuinely experienced. Legitimize, then redirect to functional recovery.